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ABSTRACT
Identifying low-abundance mutations within
wild-type DNA is important in several fields of
medicine, including cancer, prenatal diagnosis and
infectious diseases. However, utilizing the clinical
and diagnostic potential of rare mutations is
limited by sensitivity of the molecular techniques
employed, especially when the type and position of
mutations are unknown. We have developed a novel
platform that incorporates a synthetic reference
sequence within a polymerase chain reaction
(PCR) reaction, designed to enhance amplification
of unknown mutant sequences during COLD-PCR
(CO-amplification at Lower Denaturation tempera-
ture). This new platform enables an Improved and
Complete Enrichment (ice-COLD-PCR) for all
mutation types and eliminates shortcomings of
previous formats of COLD-PCR. We evaluated ice-
COLD-PCR enrichment in regions of TP53 in serially
diluted mutant and wild-type DNA mixtures.
Conventional-PCR, COLD-PCR and ice-COLD-PCR
amplicons were run in parallel and sequenced to
determine final mutation abundance for a range of
mutations representing all possible single base
changes. Amplification by ice-COLD-PCR enriched
all mutation types and allowed identification of
mutation abundances down to 1%, and 0.1% by
Sanger sequencing or pyrosequencing, respect-
ively, surpassing the capabilities of other forms of
PCR. Ice-COLD-PCR will help elucidate the clinical
significance of low-abundance mutations and our
understanding of cancer origin, evolution,
recurrence-risk and treatment diagnostics.
INTRODUCTION
Identifying low-abundance mutations is important in
several ﬁelds of medicine, including cancer, prenatal diag-
nosis and infectious diseases (1–3). For example, in clinical
samples from inﬁltrating and multi-focal cancer types,
mutation-containing cancer cells are greatly outnumbered
by an excess of normal cells (4–6). Yet it is often very
important to identify such mutational ‘needles in a
haystack’. Low-abundance DNA mutations in heteroge-
neous specimens from precancerous or cancerous tissue
biopsies, sputum, urine, stool or circulating DNA
released in blood can cause drug resistance and can be
clinically signiﬁcant biomarkers (7). However, utilizing
the clinical and diagnostic potential of such rare mutations
is often limited by accuracy and sensitivity of the molecu-
lar techniques and methods employed. The polymerase
chain reaction (PCR) is the foundation of most molecular
applications that investigate DNA sequence variation.
Several methods can enrich low-abundance mutations at
pre-determined positions during PCR ampliﬁcation (8).
However, when the position and type of such mutations
on the DNA sequence is unknown there are very few
approaches that can enrich mutations such that they can
be identiﬁed by downstream technologies (8).
CO-ampliﬁcation of major and minor alleles at Lower
Denaturation temperature [COLD-PCR (9)] is a recently
developed PCR approach capable of enriching low-
abundance mutants at any position on the sequence.
COLD-PCR operates by incorporating a critical denatur-
ation temperature (Tc) for a given DNA sequence. At the
Tc, the percent of amplicons that denature is dependent on
the exact melting properties of the interrogated DNA
sequence, thereby single point mutations or micro-
deletions inﬂuence substantially the balance of the result-
ing single and double-stranded DNA molecules. In
COLD-PCR, the Tc and cycling employed is such that
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DNA molecules that denature preferentially over
wild-type (WT) duplexes, by means of their reduced
melting temperature. Accordingly, mutation-containing
sequences become preferentially ampliﬁed during ampliﬁ-
cation. This simple principle enables COLD-PCR to
amplify mutation-containing alleles with a several-fold se-
lectivity over WT alleles (9). Advantages of COLD-PCR
include its relative simplicity, the preferential ampliﬁca-
tion of mutant-containing DNA without the need for
cumbersome protocols or additional reagents, and the
ability to subsequently sequence the ampliﬁed product
and identify the mutation. COLD-PCR can be used in
place of conventional PCR and combined with most
downstream assays, yet it requires little to no additional
cost, time and labor. Mutation detection sensitivities have
been improved several-fold by combining COLD-PCR
with established downstream applications such as Sanger
sequencing (9–11), dHPLC analysis (9); MALDI-TOF (9),
Pyrosequencing (9), real-time TaqMan PCR (12), SSCP
(13), mutation-speciﬁc restriction enzyme digestion (14)
and high resolution melting (10,15).
Although the applications of COLD-PCR in DNA
diagnostics are proliferating (8,16) there are still disadvan-
tages in the technology as currently applied. Depending
upon the type of mutation that is of interest or the degree
of mutation enrichment required, COLD-PCR is currently
applied in either of two formats: full-COLD-PCR or fast-
COLD-PCR (9). Full-COLD-PCR enriches all possible
mutations along the sequence, though the enrichment of
mutation-containing sequences relative to wild type se-
quences is generally modest (3- to 10-fold) relative to
fast-COLD-PCR. Furthermore, in full-COLD-PCR,
several minutes of an intermediate hybridization step are
required during PCR-cycling to allow cross-hybridization
of mutant and WT alleles, making the reaction exces-
sively long. In fast-COLD-PCR, the formation of
heteroduplexes within the reaction is not required, thus
the reaction is rapid and mutations are enriched
anywhere along the sequence provided they result in an
amplicon Tm that is lower than that of the WT sequence
(Tm-reducing mutations, G:C>A:T or G:C>T:A). Fast-
COLD-PCR results to enrichments of 10- to 100-fold, and
is robust and time-efﬁcient, but is limited to enriching only
Tm-reducing mutations. The different capabilities of the
two COLD-PCR formats pose a practical obstacle, since
users have to decide in advance which of the COLD-PCR
attributes they wish to utilize, thus reducing their options.
To combine the advantages of full and fast COLD-PCR
in a single format, here we present an ice modiﬁcation of
the COLD-PCR technology. In order to enrich all
mutation types, ice-COLD-PCR employs a reference
sequence (RS) of a novel-design; the RS is engineered
such that (i) it matches the WT-sequence of the anti-sense
strand; (ii) PCR primers cannot bind to it; and (iii) it is
phosphorylated on the 30-end so that it is non-extendable
by the polymerase (Figure 1). When incorporated into
PCR reactions in excess relative to the template, the RS
binds rapidly to the amplicons (Figure 1). At a critical
denaturation temperature, the RS:WT duplexes remain
double-stranded, thereby inhibiting selectively the
ampliﬁcation of WT alleles throughout the thermocycling.
Conversely, the RS:mutant duplexes are preferentially
denatured and ampliﬁed. By using a WT-speciﬁc RS, all
variants can be effectively ampliﬁed, regardless of muta-
tional type and position. We demonstrate below that this
novel ice-COLD-PCR platform removes shortcomings of
previous COLD-PCR formats and allows for the efﬁcient
enrichment of complete mutational proﬁles. We present
our ﬁndings from evaluations of serially diluted human
cell-line DNA and genomic DNA from a human lung
adenocarcinoma tumor specimen.
MATERIALS AND METHODS
Tumor specimens and genomic DNA
Human genomic DNA (male G1471, Promega
Corporation, Madison, WI, USA) was employed as the
WT control. Genomic DNA from human cancer cell-lines
HCC2218 and HCC1008, which possess deﬁned TP53 mu-
tations in exon 8 (Supplementary Table S1), was
purchased from American Type Culture Collection. The
human cell-line PFSK-1 was also purchased from ATCC
Inc. (Manassas, VA, USA) and cultured; genomic DNA
was extracted from cultured cells using a DNeasy
TM
Figure 1. Schematic of ice-COLD-PCR. A RS (long oligonucleotide)
was designed for each amplicon. Each RS is single-stranded, WT
speciﬁc, complimentary to the sense strand, and contains a
30-non-extensible phosphate group.
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per manufacturer’s instructions.
One clinical lung adenocarcinoma tumor specimen,
TL92, that was screened in a previous investigation (11)
and found to contain a 1-bp heterozygous deletion in exon
8 (c.845del, p.Arg282del; Supplementary Table S1) was
also selected for examination. TL92 belonged to a group
of snap-frozen lung adenocarcinoma specimens obtained
from the Massachusetts General Hospital Tumor Bank
and used following Internal Review Board approval.
Following manual macro-dissection, genomic DNA was
isolated using the DNeasy
TM Blood and Tissue kit
(Qiagen Inc., Valencia, CA, USA). Genomic DNA con-
centration was quantiﬁed using a Nano-drop
TM
spectrophotometer.
Genomic DNA mixtures and conventional PCR
ampliﬁcation
To determine potential mutation enrichment, genomic
DNA from human cell-lines HCC1008, HCC2218 and
PFSK-1 and from lung adenocarcinoma specimen TL92
was serially diluted into WT DNA to generate an evalu-
ation panel. The speciﬁc mutant DNA mixtures examined
were: 10, 3, 1.0, 0.3 and 0.1% mutant-to-WT ratios. In
addition, several replicates of WT DNA (0% mutant)
were included and evaluated in parallel in each
experiment.
Primers (Table 1) were designed to amplify a 167-bp
region of TP53 exon 8 from genomic DNA in a conven-
tional PCR reaction. The conventional PCR reactions
were performed using 1  manufacturer-supplied HF
(high ﬁdelity) buffer, 1.5mM MgCl2, 0.2mM dNTPs,
0.3mM primers, 0.1  LCGreen+  dye, 5U/ml
Phusion
TM high-ﬁdelity polymerase (Finnzymes Inc.,
Woburn, MA, USA), and 50ng of genomic DNA. The
reactions were performed in real-time format, on a
SmartCycler II (Cepheid Inc., Sunnyvale, CA, USA).
Post-PCR melting and gel electrophoresis were performed
to ensure speciﬁc ampliﬁcation of the target amplicon.
Thermocycling conditions are presented in Table 2. The
167-bp amplicon was subsequently used in nested PCR/
COLD-PCR reactions that ampliﬁed two overlapping 87-
and 115-bp PCR amplicons.
Reference sequences for ice-COLD-PCR
Two reference sequences (RS) of 60- and 90-nt long
designed to enrich mutations within the 87- and 115-bp
nested PCR amplicons (RS), respectively, were
synthesized and HPLC-puriﬁed by Integrated DNA
Technologies Inc. (Coralville, IA, USA). Each RS is an
exact match to the WT amplicon, but somewhat shorter in
length, such that the maximal overlap with the priming
regions is  5bp (Table 1). Each RS contains a
30-non-extensible phosphate group to prevent extension
by the polymerase throughout the course of PCR,
Figure 1.
An RS can be designed to inhibit the ampliﬁcation of
either the sense or anti-sense strand of the WT allele.
Preliminary investigations were performed to assess both
a sense-strand RS and an anti-sense strand RS; both RS
oligonucleotides functioned with equal efﬁciency (data not
presented herein).
Initial evaluations were performed to determine the
amount of RS molecules that were necessary to sufﬁciently
inhibit ampliﬁcation of the WT allele without adversely
affecting the ampliﬁcation. We ampliﬁed and compared
RS concentrations ranging 0–100nM (data not shown).
For those conditions where ampliﬁcation was
Table 1. Oligonucleotide sequences for ice-COLD-PCR; sequence orientation is presented 50–30
Oligo Target Sequence (50–30)
RS1 (RS60)
Ex8-167F
a 167-bp amplicon GCTTCTCTTTTCCTATCCTG
Ex8-167R
a 167-bp amplicon CTTACCTCGCTTAGTGCT
p53-87-F2
a 87-bp amplicon TGGTAATCTACTGGGACG
p53-87-R
a 87-bp amplicon CGGAGATTCTCTTCCTCT
30T-p53-87F sequencing primer TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTGGTAATCTACTGGGACG
60refseq-for RS60 target region GGACGGAACAGCTTT
60refseq-rev RS60 target region CTGGCCGCGTGTCTC
RS60 60nt WT RS CTCTGTGCGCCGGTCTCTCCCAGGACAGGCACAAACACGCACCT
CAAAGCTGTTCCGTCC-phosphate
Nested-87F Nested-pyroseq TGGTAATCTACTGGGACGGAA
Biotin-nested-87R Biotinylated -pyroseq Biotin-CGGAGATTCTCTTCCTCTGTG
RS-Pyro-Seq-primer Sequencing primer TGCCTGTCCTGGGAG
RS2 (RS90)
Ex8-167F
a 167-bp amplicon GCTTCTCTTTTCCTATCCTG
Ex8-167R
a 167-bp amplicon CTTACCTCGCTTAGTGCT
p53-ex8-115F 115-bp amplicon TTGCTTCTCTTTTCCTAT
p53-ex8-115R 115-bp amplicon GCGGAGATTCTCTTC
40T-p53-115F sequencing primer TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTGCTTCTCTTTTCCTATCC
90refseq-for RS90 target region CTTCCTCTGTGCGCC
90refseq-rev RS90 target region CTATCCTGAGTAGTG
RS90 90nt WT RS CTTCCTCTGTGCGCCGGTCTCTCCCAGGACAGGCACAAACACGCACCTCAAAG
CTGTTCCGTCCCAGTAGATTACCACTACTCAGGATAG-phosphate
aPrimers previously reported in ref. (9).
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determine the degree of enrichment achieved. We
observed that 25nM was an optimal RS concentration
to allow PCR ampliﬁcation of the mutant alleles to
proceed efﬁciently while also effectively hybridizing to
the WT strands. For all remaining assays, we used
25nM RS in each ice-COLD-PCR reaction.
Determination of critical denaturation temperature, Tc
To deﬁne the critical denaturation temperatures (Tc) for
both full- and fast-COLD-PCR of a given amplicon, a WT
sample was ﬁrst ampliﬁed via conventional PCR in the
presence of an intercalating dye (LCGreen+, Idaho
Technologies Inc., Salt Lake City, UT, USA), on a
SmartCycler II (Cepheid Inc) real time PCR machine,
followed by melting curve analysis (0.2 C/s, ramping
65–98 C), to identify the melting temperature (Tm). The
Tc for full- and fast-COLD-PCR is typically 1 C below the
experimentally-derived amplicon melting temperatures
(10). Deﬁning the Tc in this empirical manner results to
robust PCR ampliﬁcation as well as substantial mutation
enrichment. Because the critical denaturation temperature
during COLD-PCR has to be controlled precisely (e.g. to
within ±0.2 C), it is important to use a thermocycler with
high temperature precision. A SmartCycler II (Cepheid
Inc.) was used in this investigation.
To determine the critical denaturation temperatures
(Tc) for ice-COLD-PCR a modiﬁed procedure was used,
as follows: RS engineered for ice-COLD-PCR are shorter
than the PCR amplicon being evaluated (Figure 1), and as
such the Tm of the RS differs from the Tm of amplicon. To
determine the Tm of the RS, primers were designed such
that an amplicon of the exact same length and sequence as
the RS was ampliﬁed from WT DNA. Next, the RS–
amplicon and the WT conventional PCR amplicon were
mixed at the appropriate concentration, and followed by
denaturation (98 C 30s), hybridization (70 C 30s), and a
melting curve analysis to generate a Tm for the hybridized
duplexes. Deﬁning the critical denaturation temperature
Table 2. PCR thermocycling conditions
PCR TYPE STEP CONDITIONS Tc
 C
Conventional PCR Initial denaturation 98 C for 30s
Thermocycling: 35 cycles 98 C for 10s
Ta for 20s
72 C for 10s
N/A
Melting Curve Ramping 0.2 C/s, 65–98 C
fast-COLD-PCR Initial denaturation 98 C for 30s
Stage 1 cycling: 5 cycles 98 C for 10s
Ta for 20s, ﬂuorescent reading
72 C for 10s
Stage 2 cycling: 20–35 cycles
a Tc for 10s
Ta for 20s, ﬂuorescent reading
72 C for 10s
87bp, Tc=85.5 C
115bp, Tc=85.4 C
Melting curve Ramping 0.2 C/s, 65–98 C
full-COLD-PCR Initial denaturation 98 C for 30s
Stage 1 cycling: 5 cycles 98 C for 10s
Ta for 20s, ﬂuorescent reading
72 C for 10s
Stage 2 cycling: 20–35 cycles
a 98 C for 10s
70 C for 30s
Tc for 10s
Ta for 20s, ﬂuorescent reading
72 C for 10s
87bp, Tc=85.5 C
115bp, Tc=85.4 C
Melting Curve Ramping 0.2 C/s, 65–98 C
ice-COLD-PCR Initial denaturation 98 C for 30s
Stage 1 cycling: 5 cycles 98 C for 10s
Ta for 20s, ﬂuorescent reading
72 C for 10s
Stage 2 cycling: 20-35 cycles
a 98 C for 10s
70 C for 30s
Tc for 10s
Ta for 20s, ﬂuorescent reading
72 C for 10s
87bp, Tc=84.1 C
115bp, Tc=83.4 C
Melting Curve Ramping 0.2 C/s, 65–98 C
Ta, annealing temperature; 60 and 55 C for the 87- and the 115-bp amplicons, respectively; Tc, Critical denaturation temperature used in
COLD-PCR reactions.
a20 and 35 cycles were performed respectively for the 87-bp and the 115-bp amplicons.
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amplicon duplex was sufﬁcient for mutation enrichment
using either RS.
Analysis of full- and ice-COLD-PCR hybridization times
and thermocycling conditions
Both full-COLD-PCR and ice-COLD-PCR thermocycling
strategies include a hybridization step to allow
cross-hybridization of mutant and WT alleles form
heteroduplex molecules. Furthermore, in the original de-
velopment of full-COLD-PCR (9), several minutes of an
intermediate hybridization step (at 70 C) was necessary to
achieve optimal hybridization, making the reaction exces-
sively long. In this evaluation, we employ a high-ﬁdelity
polymerase system, Phusion (Finnzymes, Inc.) and its re-
spective proprietary buffer. Evaluations were performed
to assess the optimal hybridization time for full-
COLD-PCR and ice-COLD-PCR thermocycling using
the Phusion polymerase system. Thermocycling conditions
are presented in Table 2, however, the hybridization times
were modiﬁed in each ampliﬁcation platform (full and ice);
for both thermocycling platforms, hybridization times of
10s, 30s, 1, 2 and 5min were examined. A Tm-equivalent
(HCC1008 cell-line DNA; c.841G>C, p.Asp281His), and
a3 %Tm-increasing (PFSK-1 cell-line DNA, c.823T>G;
p.Cys275Gly), 3% mutant:WT mixture was evaluated for
each amplicon (87 and 115bp). Amplicons were Sanger
sequenced, and mutation abundance was assessed. After
analysis [based on comparisons within this investigation,
and comparison with previous studies (9)], a 30s hybrid-
ization was determined to be the optimal hybridization
time for both platforms, and was used in the remaining
method development and assays.
Evaluation of ice-COLD-PCR and comparison to other
forms of COLD-PCR
Using a 1:500 dilution of the 167-bp TP53 exon 8
amplicon as template, two 87- and 115-bp regions were
ampliﬁed via nested PCR/COLD-PCR reactions and
evaluated for low-abundance mutations. Four ampliﬁca-
tion strategies were followed: (i) conventional PCR, (ii)
full-COLD-PCR, (iii) fast-COLD-PCR and (iv) ice-
COLD-PCR. Mutant mixtures (10, 3, 1.0, 0.3 and 0.1%)
were evaluated for each reaction type. TP53 exon 8 was
ampliﬁed using the primers presented in Supplementary
Table S1.
Conventional PCR reactions were performed as
described above for the 167-bp amplicon, however
nested primers (Table 1) were used to generate 87- and
115-bp amplicons. Thermocycling conditions are as
described above except that annealing temperatures were
60 and 55 C for each target region, respectively.
Full-COLD-PCR reactions were performed using 1 
manufacturer-supplied HF (high ﬁdelity) buffer, 1.5mM
MgCl2, 0.2mM dNTPs, 0.3mM primers, 0.1 
LCGreen+  dye (Idaho Technologies), 5U/ml
Phusion
TM high ﬁdelity polymerase (Finnzymes) and 1ml
diluted (1:500) 167-bp PCR amplicon. COLD-PCR was
performed on a SmartCycler II (Cepheid Inc);
full-COLD-PCR thermocycling included ﬁve initial PCR
cycles using a conventional denaturation temperature
(98 C) to build-up the intended target amplicon from
template DNA, and then continued using the critical de-
naturation temperature and a hybridization step with full-
COLD-PCR reaction conditions. Thermocycling condi-
tions are presented in Table 2.
Fast-COLD-PCR reactions were performed using
reagent conditions as described above in the full-
COLD-PCR section. All COLD-PCR reactions were per-
formed on a SmartCycler II (Cepheid Inc). As in full-
COLD-PCR, fast-COLD-PCR thermocycling included
ﬁve initial PCR cycles using a conventional denaturation
temperature (98 C) to build-up the intended target
amplicon from template DNA, and then continued using
the critical denaturation temperature with fast-
COLD-PCR reaction conditions. Thermocycling condi-
tions are presented in Table 2.
Ice-COLD-PCR reactions were performed in the
presence of the appropriate RS, at 25nM concentration.
After determining the appropriate Tc for ice-COLD-PCR
as described earlier, PCR ampliﬁcation was performed on
the mutant mixtures (10, 3, 1.0, 0.3 and 0.1% mutant) and
WT control samples. Ice-COLD-PCR reactions were per-
formed on the Cepheid SmartCycler II, using reagent con-
ditions as described above in the full-COLD-PCR section
and 25nM RS. As in full-COLD-PCR, ice-COLD-PCR
thermocycling included ﬁve initial PCR cycles using a con-
ventional denaturation temperature (98 C) to build-up the
intended target amplicon from template DNA, and then
continued using the critical denaturation temperature
and amplicon hybridization within the ice-COLD-PCR
reaction conditions. Thermocycling conditions are pre-
sented in Table 2.
Sanger sequencing and pyrosequencing
Mutation enrichment via each PCR ampliﬁcation
approach was ﬁrst evaluated by Sanger sequencing
analysis. PCR/COLD-PCR products were subjected to di-
gestion by exonuclease I (New England Biolabs, Ipswich,
MA, USA) and shrimp alkaline phosphatase (USB
Corporation, Cleveland, OH, USA) and sequenced at
the Dana-Farber Cancer Institute, Molecular Biology
Core Facility. Sequencing primers are presented in
Table 1; due to the short length of the amplicons, a
poly-T sequence was added to the 50-end of the forward
sequencing primer. Sequence chromatograms were
evaluated using BioEdit
TM biological sequence alignment
editor (http://www.mbio.ncsu.edu/BioEdit/BioEdit.html).
Approximate mutant nucleotide abundances, relative to
the WT nucleotide, were calculated from the peak height
values of the chromatograms.
Mutation enrichment was also evaluated via
pyrosequencing analysis for selected samples. For
pyrosequencing analysis, the 87-bp COLD-PCR/ice-
COLD-PCR amplicons were ampliﬁed using
50-biotinylated reverse primers (Table 1). A serial
dilution (10, 3, 1, 0.3, 0.1 and 0%) of the HCC1008
Tm-equivalent mutation was evaluated. Amplicons were
processed for pyrosequencing analysis at EpigenDx Inc.
(Worcester, MA, USA). Mutant nucleotide abundances,
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pyrophosphate peak height values of the pyrograms.
Pyrograms were analyzed to compare the enrichment
obtained via full-COLD-PCR and ice-COLD-PCR, and
to determine the sensitivity of pyrosequencing compared
to that of Sanger sequencing.
To assess variability and reproducibility, conventional
and COLD-PCR reactions and sequencing evaluations
were repeated independently, at least three times, on
multiple days throughout several months, and were per-
formed interchangeably within wells of two SmartCycler
II (Cepheid) units.
RESULTS
Hybridization time and thermocycling protocols for
full-COLD-PCR and ice-COLD-PCR
Evaluation of varying hybridization times (30s–5min)
revealed that using Phusion high-ﬁdelity polymerase
(Finnzymes Inc.), and its proprietary buffer, that the ori-
ginally determined extended hybridization step does not
improve the enrichment, within either full-COLD-PCR or
ice-COLD-PCR ampliﬁcation (Supplementary Figures S1
and S2). Speciﬁcally, increasing the hybridization time
from 30s to 5min does not appreciably inﬂuence the
degree of enrichment. The 30-s hybridization time
achieves higher enrichment than previously observed
using the original full-COLD-PCR hybridization times
with the alternative polymerase systems and buffers (9).
Accordingly, the use of the Phusion polymerase and buffer
presumably results in faster and more efﬁcient hybridiza-
tion of DNA strands during COLD-PCR and provides an
improvement for ice-COLD-PCR as well as for full-
COLD-PCR.
Evaluation of RS60, 87-bp amplicon
Four mutation types (Tm-increasing variant, Tm-equiva-
lent variant, Tm-reducing variant and a Tm-reducing
single-base deletion), at an initial 3% mutation abun-
dance, were interrogated using the four PCR platforms
(conventional, full-COLD-PCR, fast-COLD-PCR and
ice-COLD-PCR). After ampliﬁcation, Sanger sequence
chromatograms were directly compared. Ice-COLD-PCR
yielded  13-fold enrichment for Tm-increasing
(Figure 2A; representative triplicate sequences are pre-
sented in Supplementary Figure S3) and Tm-equivalent
mutations (Figure 2B; representative triplicate sequences
are presented in Supplementary Figure S4), and  15-fold
enrichment for Tm-reducing mutations (Figure 2C and D;
representative triplicate sequences are presented in
Supplementary Figures S5 and S6 for the Tm-reducing
C>T mutation and the 1-bp [G] deletion in the lung
adenocarcinoma specimen, respectively). Full-
COLD-PCR demonstrated  5- to 8-fold enrichment for
all mutations. Furthermore, fast-COLD-PCR, which can
only enrich Tm-reducing mutations, exhibited  15- to
17-fold enrichment for these types of mutations, while
the Tm-increasing and Tm-equivalent mutations remained
undetectable. Regardless of mutant type and position,
after ice-COLD-PCR ampliﬁcation all mutation types
are strongly enriched and can be reliably identiﬁed in
Sanger sequence chromatograms down to at least 1%
mutation abundance (Supplementary Figure S7). While
full-COLD-PCR exhibited the ability to modestly enrich
each of the mutation types evaluated and assessed by
Sanger sequencing analysis, the enrichment revealed by
ice-COLD-PCR was signiﬁcantly more pronounced
(data for the 87-bp amplicon is presented in Figure 3).
Furthermore, while fast-COLD-PCR was unable to
enrich Tm-increasing and Tm-equivalent mutations, ice-
COLD-PCR was efﬁcient in enriching all mutation types
including the single-base deletion (Figure 3).
As an alternative to Sanger sequencing chromatograms,
pyrograms of full-COLD-PCR and ice-COLD-PCR
amplicons of the serially diluted mutant mixtures were
also compared (Figure 4). In the 87-bp amplicon,
pyrosequencing analysis of full-COLD-PCR amplicons
demonstrated moderate enrichment of the HCC1008 Tm-
equivalent mutation. For example, in the pyrograms the
10% mutant-to-WT mixture appeared enriched by just
>2-fold to  23%, after background subtraction. The
mutation was detectable in serial dilution mixtures down
to 1%, and demonstrated  3.5-fold enrichment to an
abundance of 3.5% (Figure 4). Analysis of the pyrograms
for ice-COLD-PCR exhibited higher levels of enrichment
and sensitivity over full-COLD-PCR. After background
subtraction, the 10% mixture, ampliﬁed by ice-
COLD-PCR, presented a 5.5-fold increase to  55%.
The mutation remained visible throughout the remaining
serial dilution mixtures. The 1% mutant mixture ampliﬁed
by ice-COLD-PCR exhibited  34-fold enrichment and the
0.1% mutant mixture, exhibited  75-fold enrichment.
Evaluation of RS90, 115-bp amplicon
The size of the sequence interrogated via ice-COLD-PCR
is deﬁned by the size of the RS. To evaluate ice-
COLD-PCR for larger sequences, a 115-bp PCR
amplicon combined with a 90-nt RS were examined
next. The same four mutation types (Tm-increasing
variant, Tm-equivalent variant, Tm-reducing variant, and
a Tm-reducing deletion) were interrogated using the four
PCR platforms (conventional, full-COLD, fast-COLD
and ice-COLD-PCR). After ampliﬁcation, Sanger
sequence chromatograms were directly compared and
evaluated. Ice-COLD-PCR yielded  13- to 15-fold enrich-
ment for Tm-increasing and Tm-equivalent mutations
(Supplementary Figure S8A), and  16-fold enrichment
for Tm-reducing mutations. In contrast, full-COLD-PCR
demonstrated  5- to 7-fold enrichment for Tm-increasing
and Tm-equivalent mutations, and  10-fold for the Tm-
reducing mutations (Supplementary Figure S8A).
Furthermore, fast-COLD-PCR, which can only enrich
Tm-reducing mutations, exhibited  16-fold enrichment
for these types of mutations, while the Tm-increasing
and Tm-equivalent mutations remained undetectable.
Regardless of mutant type and position, after ice-
COLD-PCR ampliﬁcation, all mutation types are
strongly enriched and can be reliably sequenced down to
at least 1% mutation abundance (Supplementary Figure
S8B).
e2 Nucleic AcidsResearch, 2011,Vol. 39,No. 1 PAGE 6 OF 10Figure 2. Comparison of a 87-bp PCR ampliﬁcation approaches for (A) a low-abundance (3%) Tm-increasing mutation (PFSK-1 cell-line DNA,
c.823T>G; p.Cys275Gly), (B) a low-abundance (3%) Tm-equivalent mutation (HCC1008 cell-line DNA; c.841G>C, p.Asp281His), (C)a
low-abundance (3%) Tm-reducing mutation (HCC2218 cell-line DNA; c.847C>T, p.Arg283Cys) and (D) a low-abundance (3%) Tm-reducing one
base pair deletion (c.845del, p.Arg282del) in DNA from a clinical lung adenocarcinoma specimen. Representative chromatograms are presented;
estimates of fold improvement are based upon multiple evaluations.
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The use of PCR-based enrichment methods is often neces-
sary to elevate the mutant abundance to a level at which
accurate and precise analysis is possible; however, it
remains quite difﬁcult to enrich for mutations that are
unknown and at low-abundance. While there are many
approaches to enrich low-abundance mutations of a
known status and identity, there are very few
methodologies capable of enriching and identifying all
forms of unknown mutations (8,17,18). To detect
low-abundance early mutations in tumors or the emer-
gence of resistance mutations (e.g. at levels 10
 3 to 10
 6
mutant-to-WT DNA), both high selectivity and the en-
richment of minority alleles is required for successful de-
tection and identiﬁcation. Furthermore, in order to use a
particular approach as a routine diagnostic tool, there
must be a balance of achieving high selectivity and enrich-
ment while maintaining accuracy, convenience and low
cost.
We demonstrated that the inclusion of long (60 or 90nt)
specially-designed oligonucleotides (RS) within
COLD-PCR reactions selectively enhances denaturation
of mutant over WT sequences throughout PCR, while
also reducing time-intensive hybridization times. Our
evaluations of the hybridization time at 70 C (30s–
5min) revealed that the use of the Phusion polymerase
and proprietary buffer presumably results in faster and
more efﬁcient hybridization of DNA strands during
COLD-PCR and provides an improvement for ice-
COLD-PCR as well as for full-COLD-PCR.
The utilization of long sequences to improve differential
denaturation of heteroduplexed versus homoduplexed se-
quences has not been attempted previously, and is distinct
from the use of short, WT-blocking hybridization probes
(19) or PNA/LNA-modiﬁed oligonucleotides that enrich
Figure 4. Pyrosequencing analysis of the 87-bp amplicon; pyrograms are presented for (A) full-COLD-PCR and (B) ice-COLD-PCR. Serial dilutions
(3, 1, 0.3, 0.1 and 0%) of HCC1008 (c.841 G>C, p.Asp281His) in WT DNA are presented.
Figure 3. Fold-enrichment estimates for the 87-bp amplicon by PCR
ampliﬁcation platform for 3% abundance of a Tm-increasing (T>G),
Tm-equivalent (G>C), and Tm-reducing (C>T) mutations after amp-
liﬁcation by conventional PCR, full-COLD-PCR and ice-COLD-PCR,
as analyzed by standard Sanger sequencing.
e2 Nucleic AcidsResearch, 2011,Vol. 39,No. 1 PAGE 8 OF 10for speciﬁc mutations (20,21). It is also conceivable to
introduce modiﬁed bases within a RS to improve selective
denaturation even further during ice-COLD-PCR. Using
an oligonucleotide synthesizer to construct the RS is con-
venient but has oligonucleotide-length limitations.
Alternatively, longer RS can be synthesized using asym-
metric PCR approaches, followed by end-modiﬁcation of
the single stranded DNA products.
We presented our evaluations of ice-COLD-PCR, in
comparison with the other COLD-PCR platforms and
conventional PCR, in serially diluted human cell-line
genomic DNA as well as genomic DNA extracted from
a human lung adenocarcinoma tumor specimen. Overall,
the data indicate that ice-COLD-PCR provides a highly
sensitive, rapid and economical approach for mutation
enrichment, which simultaneously allows for direct
sequencing for all types of unknown low-abundance mu-
tations. While fast-COLD-PCR retains its edge in
mutation enrichment, ice-COLD-PCR is most appropriate
for use when the user is interested in examining all
mutation types, particularly those that are unknown.
Through the inclusion of a non-amplifying WT RS,
ice-COLD-PCR demonstrates the ability to increase the
mutational abundance >50% (relative to the WT allele);
enrichment >50% cannot be achieved using full-
COLD-PCR due to the unavoidable ampliﬁcation of
those WT alleles that form the heteroduplex with the
mutant alleles. The data herein demonstrate that in
addition to Tm-reducing mutations, low-abundance Tm-
increasing and Tm-equivalent mutations can be enriched
easily, robustly and rapidly via ice-COLD-PCR, and then
subsequently identiﬁed through sequencing. The data also
indicate that there is a clear sensitivity advantage to
analyzing ice-COLD-PCR amplicons via pyrosequencing.
While Sanger sequencing of ice-COLD-PCR amplicons
demonstrated the ability to identify a 1% mutant,
pyrosequencing allows the user to identify a 0.1%
mutant mixture, demonstrating a 10-fold advantage in
sensitivity based upon sequencing-methodology.
We observed an inverse relation in the enrichment po-
tential relative to the initial mutation abundance, depend-
ing upon the type of mutant being enriched, the mutation
abundance present in the un-ampliﬁed sample, and the
sequencing method used for validation. For example, in
Sanger sequencing chromatograms, 1% mutation abun-
dances exhibited proportionally higher levels of enrich-
ment (i.e.  20-fold) than 10% mutant abundances
( 4-fold); however, below 1% it remained difﬁcult to
identify the mutation fraction in Sanger sequence chro-
matograms. On the other hand, analysis of the 87-bp
ice-COLD-PCR amplicons by pyrosequencing illustrates
more clearly this inverse trend. For example, while the
10% mutant mixture exhibited  5.5-fold enrichment, the
1% mutant mixture presented  35-fold enrichment, and
the 0.1% mutant mixture exhibited  75-fold enrichment.
This property suggests that COLD-PCR can potentially
reveal mutations present at extremely low abundances in
clinical specimens, especially when combined with sensi-
tive downstream sequencing such as pyrosequencing or
next generation sequencing. Thereby it may be possible
to investigate the potential biological signiﬁcance of
traces of somatic mutations in cancer and mutator pheno-
types (22).
Ice-COLD-PCR is expected to be beneﬁcial in discern-
ing the presence of intratumoral heterogeneity in clinical
specimens, identifying the evolution of mutation spectra,
and monitoring treatment response and disease progres-
sion. This approach may also be particularly valuable in
detecting pre-cancerous genetic changes, screening mito-
chondrial DNA or DNA isolated from bodily ﬂuids,
deﬁning tumor margins, and identifying mutations in
cases where tumor cells are diffused within WT cells,
such as in cancer formations in the pancreas and human
airways (23). Applications of COLD-PCR in identifying
fetal alleles in maternal circulation for pre-natal diagnosis
have also been envisioned (24). In all such scenarios where
mutations and variants are present at low-abundance, ice-
COLD-PCR can be a powerful option for discrete enrich-
ment of mutational events, such that downstream muta-
tional identiﬁcation becomes feasible.
CONCLUSIONS
In conclusion, we have developed ice-COLD-PCR, an ad-
vantageous platform appropriate for the discovery and
identiﬁcation of low-abundance unknown mutations and
allele-variants. The inclusion of an appropriately designed
RS within COLD-PCR selectively inhibits WT ampliﬁca-
tion throughout PCR, while preferentially enriches
mutants and reducing time-intensive hybridization times.
Ice-COLD-PCR combines high sensitivity, speed and ease
of use, and facilitates direct sequencing for all types of
unknown low-abundance mutations in clinical cancer spe-
cimens. Identifying and discerning the clinical signiﬁcance
of low-abundance mutations will have a profound inﬂu-
ence on our understanding of cancer origin, evolution,
risk, recurrence and treatment diagnostics.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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